Spinal delivery of AAV vector restores enzyme activity and increases ventilation in pompe mice

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 21-27

  Qiu, Kai ^a   Falk, Darin J ^a,b   Reier, Paul J ^a,b   Byrne, Barry J ^a,b   Fuller, David D ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLYCOGEN ANALYSIS; GLYCOGEN STORAGE DISEASE TYPE 2; IMMUNOHISTOCHEMISTRY; LUNG VENTILATION; MOUSE; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PLETHYSMOGRAPHY; RESPIRATORY FAILURE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MURINAE; MUS;

EID: 84856950003     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.214     Document Type: Article

References (50)

1. Byrne, BJ, Kishnani, PS, Case, LE, Merlini, L, Müller-Felber, W, Prasad, S et al. (2011). Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 103: 1-11.
2. Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL et al. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68: 99-109. (Pubitemid 46071892)
3. Hirschhorn, RR and Reuser, AJ (2000). Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle, D (eds). Metabolic Basis of Inherited Disease. McGraw Hill: New York. pp. 3389-3420.
4. Raben, N, Plotz, P and Byrne, BJ (2002). Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2: 145-166. (Pubitemid 34649837)
5. DeRuisseau, LR, Fuller, DD, Qiu, K, DeRuisseau, KC, Donnelly, WH Jr, Mah, C et al. (2009). Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci USA 106: 9419-9424.
6. Gambetti, P, DiMauro, S and Baker, L (1971). Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30: 412-430.
7. Mancall, EL, Aponte, GE and Berry, RG (1965). Pompe's disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 24: 85-96.
8. Martin, JJ, de Barsy, T, van Hoof, F and Palladini, G (1973). Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol 23: 229-244.
9. Martini, C, Ciana, G, Benettoni, A, Katouzian, F, Severini, GM, Bussani, R et al. (2001). Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 57: 906-908. (Pubitemid 32845520)
10. Teng, YT, Su, WJ, Hou, JW and Huang, SF (2004). Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 27: 379-384.
11. Matsui, T, Kuroda, S, Mizutani, M, Kiuchi, Y, Suzuki, K and Ono, T (1983). Generalized glycogen storage disease in Japanese quail (Coturnix coturnix japonica). Vet Pathol 20: 312-321. (Pubitemid 13073710)
12. Sidman, RL, Taksir, T, Fidler, J, Zhao, M, Dodge, JC, Passini, MA et al. (2008). Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol 67: 803-818.
13. Clement, DH and Godman, GC (1950). Glycogen disease resembling mongolism, cretinism, and amytonia congenita; case report and review of literature. J Pediatr 36: 11-30, illust.
14. Hogan, GR, Gutmann, L, Schmidt, R and Gilbert, E (1969). Pompe's disease. Neurology 19: 894-900.
15. Willemsen, MA, Jira, PE, Gabreëls, FJ, van der Ploeg, AT and Smeitink, JA (1998). [Three hypotonic neonates with hypertrophic cardiomyopathy: Pompe's disease]. Ned Tijdschr Geneeskd 142: 1388-1392. (Pubitemid 28302871)
16. Zellweger, H, Dark, A and Abu-Haidar, GA (1955). Glycogen disease of skeletal muscle; report of two cases and review of literature. Pediatrics 15: 715-732.
17. Burrow, TA, Bailey, LA, Kinnett, DG and Hopkin, RJ (2010). Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 42: 455-458.
18. Rohrbach, M, Klein, A, Köhli-Wiesner, A, Veraguth, D, Scheer, I, Balmer, C et al. (2010). CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33: 751-757.
19. Raben, N, Nagaraju, K, Lee, E, Kessler, P, Byrne, B, Lee, L et al. (1998). Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273: 19086-19092. (Pubitemid 28366303)
20. Kikuchi, T, Yang, HW, Pennybacker, M, Ichihara, N, Mizutani, M, Van Hove, JL et al. (1998). Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 101: 827-833. (Pubitemid 28096080)
21. Raben, N, Danon, M, Gilbert, AL, Dwivedi, S, Collins, B, Thurberg, BL et al. (2003). Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80: 159-169. (Pubitemid 37272242)
22. Jones, HN, Muller, CW, Lin, M, Banugaria, SG, Case, LE, Li, JS et al. (2010). Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 25: 277-283.
23. Muller, CW, Jones, HN, O'Grady, G, Suarez, AH, Heller, JH and Kishnani, PS (2009). Language and speech function in children with infantile Pompe disease. J Pediatr Neurol 7: 147-156.
24. Burger, C, Gorbatyuk, OS, Velardo, MJ, Peden, CS, Williams, P, Zolotukhin, S et al. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317. (Pubitemid 39117875)
25. Qiu, K, Lane, MA, Lee, KZ, Reier, PJ and Fuller, DD (2010). The phrenic motor nucleus in the adult mouse. Exp Neurol 226: 254-258.
26. Chamberlin, NL, Du, B, de Lacalle, S and Saper, CB (1998). Recombinant adenoassociated virus vector: use for transgene expression and anterograde tract tracing in the CNS. Brain Res 793: 169-175. (Pubitemid 28294084)
27. Lane, MA, White, TE, Coutts, MA, Jones, AL, Sandhu, MS, Bloom, DC et al. (2008). Cervical prephrenic interneurons in the normal and lesioned spinal cord of the adult rat. J Comp Neurol 511: 692-709.
28. Qiu, K, Lane, MA, Lee, KZ, Reier, PJ and Fuller, DD (2010). The phrenic motor nucleus in the adult mouse. Exp Neurol 226: 254-258.
29. Guth, L and Watson, PK (1968). A correlated histochemical and quantitative study on cerebral glycogen after brain injury in the rat. Exp Neurol 22: 590-602.
30. Hlastala, MP and Berger, AJ (2001). Physiology of Respiration. Oxford University Press: New York. pp. 65-80.
31. Peel, AL, Zolotukhin, S, Schrimsher, GW, Muzyczka, N and Reier, PJ (1997). Efficient transduction of green fluorescent protein in spinal cord neurons using adenoassociated virus vectors containing cell type-specific promoters. Gene Ther 4: 16-24. (Pubitemid 27073218)
32. Mah, CS, Falk, DJ, Germain, SA, Kelley, JS, Lewis, MA, Cloutier, DA et al. (2010). Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 18: 502-510.
33. Mah, CS, Falk, DJ, Germain, SA, Kelley, JS, Lewis, MA, Cloutier, DAet al. (2010). Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 18: 502-510.
34. Burghaus, L, Liu, W, Neuen-Jacob, E, Gempel, K and Haupt, WF (2006). [Glycogenesis Type II (M. Pompe). Selective failure of the respiratory musculature-a rare first symptom]. Nervenarzt 77: 181-2, 185-186.
35. Pellegrini, N, Laforet, P, Orlikowski, D, Pellegrini, M, Caillaud, C, Eymard, B et al. (2005). Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 26: 1024-1031. (Pubitemid 41829932)
36. Fraites, TJ Jr, Schleissing, MR, Shanely, RA, Walter, GA, Cloutier, DA, Zolotukhin, I et al. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 5(5 Pt 1): 571-578. (Pubitemid 34546087)
37. Rucker, M, Fraites, TJ Jr, Porvasnik, SL, Lewis, MA, Zolotukhin, I, Cloutier, DA et al. (2004). Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development 131: 3007-3019. (Pubitemid 38997287)
38. Kishnani, PS and Howell, RR (2004). Pompe disease in infants and children. J Pediatr 144 (suppl. 5): S35-S43. (Pubitemid 38591273)
39. Mah, C, Pacak, CA, Cresawn, KO, Deruisseau, LR, Germain, S, Lewis, MA et al. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 15: 501-507.
40. Rohrbach, M, Klein, A, Kohli-Wiesner, A, Veraguth, D, Scheer, I, Balmer, C et al. (2010). CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33: 751-757.
41. Lee, KZ, Qiu, K, Sandhu, MS, Elmallah, MK, Falk, DJ, Lane, MA et al. (2011). Hypoglossal neuropathology and respiratory activity in pompe mice. Front Physiol 2: 31.
42. Bankiewicz, KS, Forsayeth, J, Eberling, JL, Sanchez-Pernaute, R, Pivirotto, P, Bringas, J et al. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14: 564-570. (Pubitemid 44296090)
43. Mandel, RJ, Manfredsson, FP, Foust, KD, Rising, A, Reimsnider, S, Nash, K et al. (2006). Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13: 463-483. (Pubitemid 43257615)
44. Beck, M (2010). Therapy for lysosomal storage disorders. IUBMB Life 62: 33-40.
45. Van den Hout, JM, Kamphoven, JH, Winkel, LP, Arts, WF, De Klerk, JB, Loonen, MC et al. (2004). Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: e448-e457.
46. Levine, JC, Kishnani, PS, Chen, YT, Herlong, JR and Li, JS (2008). Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 29: 1033-1042.
47. Sugai, F, Kokunai, Y, Yamamoto, Y, Hashida, G, Shimazu, K, Mihara, M et al. (2010). Use of the muscle volume analyzer to evaluate enzyme replacement therapy in lateonset Pompe disease. J Neurol 257: 461-463.
48. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167. (Pubitemid 35341079)
49. Drorbaugh, JE and Fenn, WO (1955). A barometric method for measuring ventilation in newborn infants. Pediatrics 16: 81-87.
50. Packard GC, Boardman, TJ (1999). The use of percentages and size-specific indices to normalize physiological data for variation in body size: wasted time, wasted efforti Comp Biochem Physiol A Mol Integr Physiol 122: 37-44. (Pubitemid 29118244)